GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sachin Jain
BofA Securities, Research Division

Sachin Jain here from the European team, Bank of America. It’s my pleasure to be hosting Glaxo. We have Julie Brown, CFO, Tony Wood, Head of R&D; and then IR folks, Constantin and Mick in the front. We have about 40 minutes, and I’ll aim to split it roughly half-half between Julie and Tony, but perhaps if you wanted to make some introductory comments and we’ll get into questions.

Julie Brown
CFO & Executive Director

Yes, sure. Good morning, everybody. Good to see everybody. So obviously, in GSK, we’re very focused on four major therapeutic areas. We’ve had a good year so far. We’ve upgraded to the top end of the guidance range for the year. And very importantly, the Specialty business is driving a considerable amount of the growth. Oncology is performing extremely well, as I’m sure we’ll talk about, together with Respiratory, Immunology and Inflammation. And the HIV business is equally with the new 2-month long-acting is really performing well. We have got also long-term guidance out in the market, which is more than GBP 40 billion by 2031 in terms of sales. And we’ve had a really good track record. We had 13 Phase III positive readouts last year.

We’re on track for five major approvals this year and four launches this year with the major ones being Blenrep and also depemokimab coming at the end of the year for respiratory, asthma. So I think in terms of overall shape, we’re a growth-orientated company with a lot